#biotech #GSK #Nuvalent #MandA #GSK #Nuvalent #Oncology #lungcancer #antibodydrugconjugate #ADC #ALKinhibitor #NSCLC #ROS1positiveNSCLC #ALKpositiveNSCLC #RAPTTherapeutics #Liverfibrosis #Engitix #liverfibrosis #Hepatology #BostonTherapeutics #SLD #chronichepatitisBtherapy
zurl.co/6i8wS
zurl.co/6i8wS
GSK pursues $10.6bn takeover of cancer biotech Nuvalent
GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
zurl.co
June 10, 2026 at 11:54 AM